Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth
04:34pm, Thursday, 30'th Apr 2020
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stifel Nicolaus Remains a Hold on Amarin (AMRN)
04:07pm, Thursday, 30'th Apr 2020
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Amarin (AMRN), with a price target of $8.00. The company's
Stifel Nicolaus Remains a Hold on Amarin (AMRN)
04:07pm, Thursday, 30'th Apr 2020
In a report released today,
Derek Archila
from Stifel Nicolaus reiterated a
Hold
rating on Amarin (
AMRN
–
Research Report
), with a price target of
$8.00
. The company’s shares closed last Thursd
PCRX or CTLT: Which Is the Better Value Stock Right Now?
03:40pm, Thursday, 30'th Apr 2020
PCRX vs. CTLT: Which Stock Is the Better Value Option?
Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020
11:30am, Thursday, 30'th Apr 2020
Pacira BioSciences, Inc. (PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 7, 2020. International callers may dial 1-
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $52
10:42am, Thursday, 30'th Apr 2020Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
09:46am, Thursday, 30'th Apr 2020
After Northland Securities and Wedbush gave Pacira Pharmaceuticals (NASDAQ: PCRX) a Buy rating last month, the company received another Buy, this time
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
09:46am, Thursday, 30'th Apr 2020
After Northland Securities and Wedbush gave Pacira Pharmaceuticals (NASDAQ: PCRX) a Buy rating last month, the company received another Buy,
ARP Americas LP Takes Position in Pacira Biosciences Inc (NASDAQ:PCRX)
08:36am, Thursday, 30'th Apr 2020
ARP Americas LP acquired a new stake in Pacira Biosciences Inc (NASDAQ:PCRX) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 14,732
Pacira Biosciences Inc (NASDAQ:PCRX) Expected to Post FY2024 Earnings of $2.95 Per Share
07:30am, Thursday, 30'th Apr 2020
Pacira Biosciences Inc (NASDAQ:PCRX) – Equities research analysts at Wedbush increased their FY2024 earnings per share estimates for shares of Pacira Biosciences in a research note issued on Monday,
Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth
12:00am, Thursday, 30'th Apr 2020How Much Did Pacira BioSciences, Inc.’s (NASDAQ:PCRX) CEO Pocket Last Year?
02:26pm, Wednesday, 29'th Apr 2020
Dave Stack has been the CEO of Pacira BioSciences, Inc. (NASDAQ:PCRX) since 2007. This report will, first, examine the...
Pacira Biosciences' (PCRX) "Buy" Rating Reiterated at Wedbush
07:08am, Tuesday, 28'th Apr 2020
Pacira Biosciences (NASDAQ:PCRX)‘s stock had its “buy” rating reissued by research analysts at Wedbush in a note issued to investors on Monday, TipRanks reports. They presently have a $85.00 tar
Pacira Pharmaceuticals (PCRX) Gets a Buy Rating from Wedbush
06:10pm, Monday, 27'th Apr 2020
Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals (PCRX) today and set a price target of $85.00. The company's shares
Pfizer (PFE) Receives a Buy from RBC Capital
10:23am, Monday, 27'th Apr 2020
In a report released today, Randall Stanicky from RBC Capital maintained a Buy rating on Pfizer (PFE), with a price target of $44.00. The company's shares
